Abstract
Psoriasis is a chronic systemic inflammatory disease characterized by topical skin lesions as well as an increased risk for cardiovascular disease (CVD). There is also increasing evidence that patients with psoriasis are more prone to several CVD risk factors (hypertension, obesity, dyslipidemia and smoking), non-cardiac vascular diseases (carotid, peripheral artery and chronic kidney disease) and metabolic co-morbidities (type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease and obstructive sleep apnea) compared with the general population. The associations are even greater in patients with severe psoriasis and those with psoriatic arthritis. Insulin resistance, endothelial dysfunction and obesity induced by several adipokines and inflammatory cytokines are proposed as the common mechanisms linking psoriasis with CVD, vascular risk factors and metabolic diseases.
The present narrative review considers the associations between psoriasis (and psoriatic arthritis) with CVD, vascular risk factors and metabolic diseases. Drugs that reduce CVD risk and improve metabolic parameters may also beneficially affect psoriasis severity and prognosis. Furthermore, anti-psoriatic drugs can exert different effects on CVD risk and metabolic co-morbidities. Therefore, physicians should be aware of these associations in order to adequately monitor and treat psoriatic patients.
Keywords: Cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, psoriasis, psoriatic arthritis, vascular risk factors.
Current Pharmaceutical Design
Title:Psoriasis and Vascular Risk : An Update
Volume: 20 Issue: 39
Author(s): Niki Katsiki, Panagiotis Anagnostis, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, psoriasis, psoriatic arthritis, vascular risk factors.
Abstract: Psoriasis is a chronic systemic inflammatory disease characterized by topical skin lesions as well as an increased risk for cardiovascular disease (CVD). There is also increasing evidence that patients with psoriasis are more prone to several CVD risk factors (hypertension, obesity, dyslipidemia and smoking), non-cardiac vascular diseases (carotid, peripheral artery and chronic kidney disease) and metabolic co-morbidities (type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease and obstructive sleep apnea) compared with the general population. The associations are even greater in patients with severe psoriasis and those with psoriatic arthritis. Insulin resistance, endothelial dysfunction and obesity induced by several adipokines and inflammatory cytokines are proposed as the common mechanisms linking psoriasis with CVD, vascular risk factors and metabolic diseases.
The present narrative review considers the associations between psoriasis (and psoriatic arthritis) with CVD, vascular risk factors and metabolic diseases. Drugs that reduce CVD risk and improve metabolic parameters may also beneficially affect psoriasis severity and prognosis. Furthermore, anti-psoriatic drugs can exert different effects on CVD risk and metabolic co-morbidities. Therefore, physicians should be aware of these associations in order to adequately monitor and treat psoriatic patients.
Export Options
About this article
Cite this article as:
Katsiki Niki, Anagnostis Panagiotis, Athyros G. Vasilios, Karagiannis Asterios and Mikhailidis P. Dimitri, Psoriasis and Vascular Risk : An Update, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417105323
DOI https://dx.doi.org/10.2174/1381612820666140417105323 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene-Activation Mechanisms in the Regression of Atherosclerosis, Elimination of Diabetes Type 2, and Prevention of Dementia
Current Molecular Medicine Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Serum Uric Acid and Risk of Coronary Heart Disease
Current Pharmaceutical Design Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease
Current Pharmaceutical Design Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Non-invasive Estimation of Aortic Blood Pressures: A Close Look at Current Devices and Methods
Current Pharmaceutical Design Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science Editorial [Hot Topic: Novel Pharmacological Therapies for Cardiac Hypertrophy and Heart Failure (Executive Guest Editor: Peter M. Kang)]
Current Pharmaceutical Design Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis
Current HIV Research Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Epidemiological and Clinical Data of Amniotic Fluid Embolism in Forensic Settings
Current Pharmaceutical Biotechnology Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry The Connection Between C-Reactive Protein (CRP) and Diabetic Vasculopathy. Focus on Preclinical Findings
Current Diabetes Reviews Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued)